TG Therapeutics (TGTX) News Today $31.70 -1.66 (-4.98%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$31.53 -0.17 (-0.54%) As of 01/31/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period TG Therapeutics (NASDAQ:TGTX) Rating Lowered to Sell at StockNews.comStockNews.com downgraded shares of TG Therapeutics from a "hold" rating to a "sell" rating in a research report on Friday.January 31 at 11:08 PM | marketbeat.comConfidence in TG Therapeutics’ Growth: Buy Rating Affirmed Amid Solid Financial PerformanceJanuary 29 at 10:39 AM | markets.businessinsider.comTG Therapeutics (NASDAQ:TGTX) Stock Price Up 6.8% - Here's What HappenedTG Therapeutics (NASDAQ:TGTX) Trading Up 6.8% - Should You Buy?January 24, 2025 | marketbeat.comBrokers Set Expectations for TG Therapeutics FY2025 EarningsJanuary 24, 2025 | americanbankingnews.comTG Therapeutics: Entering 2025 With Increased Investor ExpectationsJanuary 23, 2025 | seekingalpha.comAnalysts Issue Forecasts for TG Therapeutics FY2025 EarningsTG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share estimates for TG Therapeutics in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst P. Agrawal anticipates that the biopharmaceutical compJanuary 22, 2025 | marketbeat.comAssenagon Asset Management S.A. Cuts Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)Assenagon Asset Management S.A. reduced its stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 39.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 103,080 shares of the biJanuary 22, 2025 | marketbeat.comTG Therapeutics: 2025 Revenues Will Smash ExpectationsJanuary 21, 2025 | seekingalpha.comTG Therapeutics FY2024 EPS Forecast Raised by HC WainwrightTG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Analysts at HC Wainwright boosted their FY2024 earnings per share (EPS) estimates for shares of TG Therapeutics in a research report issued on Wednesday, January 15th. HC Wainwright analyst E. White now forecasts that the biopharmaceutical compaJanuary 17, 2025 | marketbeat.comStrong Financial Outlook and Strategic Growth Opportunities Bolster Buy Rating for TG TherapeuticsJanuary 16, 2025 | markets.businessinsider.comTG Therapeutics: Cash Positive But Playing Defense (Rating Downgrade)January 16, 2025 | seekingalpha.comHC Wainwright Boosts Earnings Estimates for TG TherapeuticsTG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Equities researchers at HC Wainwright increased their FY2025 earnings per share (EPS) estimates for shares of TG Therapeutics in a report released on Wednesday, January 15th. HC Wainwright analyst E. White now expects that the biopharmaceuticalJanuary 16, 2025 | marketbeat.comIs TG Therapeutics Inc. (TGTX) Among Tuesday’s Top Gainers?January 15, 2025 | insidermonkey.comTG Therapeutics (NASDAQ:TGTX) Given "Buy" Rating at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $55.00 target price on shares of TG Therapeutics in a report on Wednesday.January 15, 2025 | marketbeat.comTG Therapeutics, Inc.: TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue and 2025 Anticipated Development MilestonesJanuary 14, 2025 | finanznachrichten.deB.Riley Financial Reaffirms Their Buy Rating on TG Therapeutics (TGTX)January 14, 2025 | markets.businessinsider.comWhy TGTX Stock Is Rallying TodayJanuary 14, 2025 | msn.comTG Therapeutics stock rises on strong Q4 and full-year revenueJanuary 14, 2025 | investing.comTG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue and 2025 Anticipated Development MilestonesJanuary 14, 2025 | finance.yahoo.comTG Therapeutics Expects Prelim. Q4 US Net Product Revenue For Briumvi At $103.6 MlnJanuary 14, 2025 | markets.businessinsider.comBank of America Securities Reaffirms Their Sell Rating on TG Therapeutics (TGTX)January 14, 2025 | markets.businessinsider.comTG Therapeutics says 2024 Briumvi sales topped expectationsJanuary 14, 2025 | msn.comTG Therapeutics (NASDAQ:TGTX) Shares Gap Up - Time to Buy?TG Therapeutics (NASDAQ:TGTX) Shares Gap Up - What's Next?January 14, 2025 | marketbeat.comWhat's Going On With TG Therapeutics Stock Tuesday?January 14, 2025 | benzinga.comTG Therapeutics, Inc. (NASDAQ:TGTX) Receives Consensus Rating of "Moderate Buy" from BrokeragesTG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) has received a consensus rating of "Moderate Buy" from the six research firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and five have assigned a buy rating toJanuary 14, 2025 | marketbeat.comTG Therapeutics: Subcutaneous Briumvi Data A Key Near-Term CatalystJanuary 14, 2025 | seekingalpha.comJPMorgan Chase & Co. Has $16.86 Million Position in TG Therapeutics, Inc. (NASDAQ:TGTX)JPMorgan Chase & Co. lifted its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 60.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 720,798 shares of the biopharmaceutical company's stockJanuary 11, 2025 | marketbeat.comTG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 9, 2025 | globenewswire.comSean A. Power Sells 10,021 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) StockJanuary 8, 2025 | insidertrades.comTG Therapeutics (NASDAQ:TGTX) Rating Increased to Hold at StockNews.comStockNews.com raised TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday.January 7, 2025 | marketbeat.comTG Therapeutics price target raised to $10 from $9 at BofAJanuary 7, 2025 | markets.businessinsider.comTG Therapeutics, Inc. (NASDAQ:TGTX) CFO Sean A. Power Sells 10,021 SharesTG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) CFO Sean A. Power sold 10,021 shares of the company's stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $28.53, for a total transaction of $285,899.13. Following the transaction, the chief financial officer now owns 660,611 shares in the company, valued at $18,847,231.83. The trade was a 1.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.January 7, 2025 | marketbeat.comInsider Selling: TG Therapeutics, Inc. (NASDAQ:TGTX) CFO Sells 11,337 Shares of StockTG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) CFO Sean A. Power sold 11,337 shares of the business's stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $30.29, for a total value of $343,397.73. Following the completion of the sale, the chief financial officer now directly owns 670,632 shares in the company, valued at approximately $20,313,443.28. This represents a 1.66 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.January 7, 2025 | marketbeat.comTG Therapeutics (NASDAQ:TGTX) Shares Down 2.9% - Here's What HappenedTG Therapeutics (NASDAQ:TGTX) Shares Down 2.9% - Here's What HappenedJanuary 6, 2025 | marketbeat.comJefferies Sticks to Their Buy Rating for TG Therapeutics (TGTX)January 5, 2025 | markets.businessinsider.comTG Therapeutics (NASDAQ:TGTX) Trading Down 2.4% - Here's What HappenedTG Therapeutics (NASDAQ:TGTX) Shares Down 2.4% - Time to Sell?December 31, 2024 | marketbeat.comPrincipal Financial Group Inc. Grows Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)Principal Financial Group Inc. boosted its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 1,549.4% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 772,188 shares of the biopharmaceuticaDecember 27, 2024 | marketbeat.comWhat to Expect from the Stock Market in 2025December 25, 2024 | finance.yahoo.comWill TG Therapeutics, Inc. (TGTX) Make You Rich In 2025?December 24, 2024 | insidermonkey.comTG Therapeutics (NASDAQ:TGTX) Downgraded by StockNews.com to SellStockNews.com downgraded TG Therapeutics from a "hold" rating to a "sell" rating in a research note on Sunday.December 22, 2024 | marketbeat.comTG Therapeutics, Inc. (NASDAQ:TGTX) Receives Consensus Rating of "Moderate Buy" from AnalystsShares of TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) have earned a consensus rating of "Moderate Buy" from the six analysts that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation toDecember 20, 2024 | marketbeat.com19,900 Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) Acquired by Synovus Financial CorpSynovus Financial Corp acquired a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund acquired 19,900 shares of the biopharmaceutical company's stock, valued at approximately $465,000. Other instDecember 19, 2024 | marketbeat.comTeachers Retirement System of The State of Kentucky Buys New Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)Teachers Retirement System of The State of Kentucky purchased a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 44,450 shares of the biopharmaceuDecember 19, 2024 | marketbeat.comTG Therapeutics, Inc. (NASDAQ:TGTX) Stock Holdings Lifted by Barclays PLCBarclays PLC lifted its position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 83.9% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 347,057 shares of the biopharmaceutical company's stock after acquiring an additionalDecember 18, 2024 | marketbeat.comExome Asset Management LLC Has $4.86 Million Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)Exome Asset Management LLC decreased its position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 17.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 207,627 shares of the biophDecember 14, 2024 | marketbeat.comTG Therapeutics (NASDAQ:TGTX) Upgraded by StockNews.com to Hold RatingStockNews.com upgraded shares of TG Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday.December 14, 2024 | marketbeat.comState Street Corp Raises Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)State Street Corp lifted its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 35.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,094,158 shares of the biopharmaceutical coDecember 12, 2024 | marketbeat.comNeo Ivy Capital Management Buys New Shares in TG Therapeutics, Inc. (NASDAQ:TGTX)Neo Ivy Capital Management bought a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 100,780 shares of the biopharmaceutical company'sDecember 11, 2024 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC cut its stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 8.7% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 293,927 shares of the biopharmaDecember 10, 2024 | marketbeat.comFmr LLC Decreases Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)Fmr LLC trimmed its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 2.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,184,158 shares of the biopharmaceutical company's stDecember 10, 2024 | marketbeat.com Get TG Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address TGTX Media Mentions By Week TGTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TGTX News Sentiment▼0.490.69▲Average Medical News Sentiment TGTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TGTX Articles This Week▼36▲TGTX Articles Average Week Get TG Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BeiGene News Summit Therapeutics News Moderna News Genmab A/S News Viatris News Intra-Cellular Therapies News Catalent News Dr. Reddy's Laboratories News Vaxcyte News Sarepta Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TGTX) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredNow that Trump’s be inaugurated, this day will be key (mark your calendar)Mark your calendar for March 13th. Because on that day, I believe we could see a $2 Trillion shock INTO the...Timothy Sykes | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TG Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TG Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
